Accelerating the Commercialization of Cancer Research Results
The Canadian Cancer Society (CCS) and the Creative Destruction Lab (CDL) have launched a new world-class accelerator program for entrepreneurs and researchers developing innovations to improve the cancer experience globally and throughout the cancer care continuum. This program will educate, coach, finance and inspire seed-stage oncology-focused companies by pairing them with mentors, industry leaders and subject matter experts. Over 9 months and 5 sessions, accepted startups will be supported to tighten their strategic objectives, raise capital and engage with partners in the field. CDL Cancer will operate through the CDL Health and CDL Neuro streams based in CDL-Toronto (University of Toronto) and CDL-Vancouver (University of British Columbia) and is now accepting applications for the CDL 2022/23 Program Year. CDL Cancer is a foundational component of CCS’s new Centre for Cancer Prevention and Support, a national hub of research and innovation for cancer prevention and support services.

In recognition of this year’s International Women’s Day, the CCRA celebrates 14 outstanding women for their contributions to cancer research. These women, all recipients of CCRA awards, have had remarkable impacts, elevati...
Today, the CCRA released its latest report on the investment in cancer research from 2005 to 2019. A grand total of $7.4 billion was invested during this 15-year period. The fluctuating investment in major infrastructure drove peaks and valleys in the overall investmen...